Richmond Pharmacologys latest research on the effect of food on the QT interval Presented at the 6th European Congress of Pharmacology 2012

Posted:
1
June 2012

Food alters the QTc and might be an attractive non-pharmacological method of confirming assay sensitivity in Thorough QT (TQT) studies. This idea was recently examined (Taubel et al., 2011) and showed that food shortens QTcF. This is important because previously it has been debated in the literature to whether euglycaemic hyperinsulinemia can prolong the QTc interval (Gastaldelli et al. 2000).The European Congress of Pharmacology will be hosted this year by the Spanish Society of Pharmacology in Granada, Spain from 17-20 July, and will bring together pharmacologists from all over the world to debate current drug research and development issues from �bench to bedside�.Following Dr Taubel�s presentation  at the DIA 3rd Cardiac Safety Workshop in Japan, he will present his latest data assessing how late changes  i.e. 2-4 hours after the end of a euglycaemic insulin clamp can lead to significant increases in QTcF in healthy subjects. The presentation will be based on a single centre, randomised, placebo- and positive-controlled study that was carried out by Richmond Pharmacology in both healthy Caucasian and Japanese subjects. The euglycaemic insulin clamp was used to investigate the effects of insulin, C-peptide and glucose on the QT interval.View the Scientific Program

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more